201 related articles for article (PubMed ID: 16278418)
21. No-carrier-added iodine-131-MIBG: evaluation of a therapeutic preparation.
Mairs RJ; Cunningham SH; Russell J; Armour A; Owens J; McKellar K; Gaze MN
J Nucl Med; 1995 Jun; 36(6):1088-95. PubMed ID: 7769433
[TBL] [Abstract][Full Text] [Related]
22. Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: pharmacokinetic and pharmacodynamic evaluation.
Guichard S; Montazeri A; Chatelut E; Hennebelle I; Bugat R; Canal P
Clin Cancer Res; 2001 Oct; 7(10):3222-8. PubMed ID: 11595718
[TBL] [Abstract][Full Text] [Related]
23. Optimizing MIBG therapy of neuroendocrine tumors: preclinical evidence of dose maximization and synergy.
Mairs RJ; Boyd M
Nucl Med Biol; 2008 Aug; 35 Suppl 1():S9-20. PubMed ID: 18707637
[TBL] [Abstract][Full Text] [Related]
24. A comparison of targeting of neuroblastoma with mIBG and anti L1-CAM antibody mAb chCE7: therapeutic efficacy in a neuroblastoma xenograft model and imaging of neuroblastoma patients.
Hoefnagel CA; Rutgers M; Buitenhuis CK; Smets LA; de Kraker J; Meli M; Carrel F; Amstutz H; Schubiger PA; Novak-Hofer I
Eur J Nucl Med; 2001 Mar; 28(3):359-68. PubMed ID: 11315605
[TBL] [Abstract][Full Text] [Related]
25. Hyperbaric oxygen enhances the effects of meta-iodobenzylguanidine (MIBG) on energy metabolism and lipid peroxidation in the human neuroblastoma cell line SK-N-BE(2C).
Cornelissen J; Van Kuilenburg AB; Elzinga L; Van der Kleij AD; Voûte PA; Van Gennip AH
Anticancer Res; 1997; 17(1A):259-64. PubMed ID: 9066662
[TBL] [Abstract][Full Text] [Related]
26. Radiosensitization of noradrenaline transporter-expressing tumour cells by proteasome inhibitors and the role of reactive oxygen species.
Rae C; Tesson M; Babich JW; Boyd M; Mairs RJ
EJNMMI Res; 2013 Nov; 3(1):73. PubMed ID: 24219987
[TBL] [Abstract][Full Text] [Related]
27. Using pharmacokinetic and pharmacodynamic modeling and simulation to evaluate importance of schedule in topotecan therapy for pediatric neuroblastoma.
Panetta JC; Schaiquevich P; Santana VM; Stewart CF
Clin Cancer Res; 2008 Jan; 14(1):318-25. PubMed ID: 18172284
[TBL] [Abstract][Full Text] [Related]
28. Cytotoxic effects of m-[131I]- and m-[125I]iodobenzylguanidine on the human neuroblastoma cell lines SK-N-SH and SK-N-LO.
Bruchelt G; Girgert R; Buck J; Wolburg H; Niethammer D; Treuner J
Cancer Res; 1988 Jun; 48(11):2993-7. PubMed ID: 3365688
[TBL] [Abstract][Full Text] [Related]
29. Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma.
Gaze MN; Chang YC; Flux GD; Mairs RJ; Saran FH; Meller ST
Cancer Biother Radiopharm; 2005 Apr; 20(2):195-9. PubMed ID: 15869455
[TBL] [Abstract][Full Text] [Related]
30. Determination of the optimal combination chemotherapy regimen for treatment of platinum-resistant ovarian cancer in nude mouse model.
Saucier JM; Yu J; Gaikwad A; Coleman RL; Wolf JK; Smith JA
J Oncol Pharm Pract; 2007 Mar; 13(1):39-45. PubMed ID: 17621566
[TBL] [Abstract][Full Text] [Related]
31. [(131)I] and [(125)I] metaiodobenzylguanidine therapy in macroscopic and microscopic tumors: a comparative study in SK-N-SH human neuroblastoma and PC12 rat pheochromocytoma xenografts.
Rutgers M; Buitenhuis CK; van der Valk MA; Hoefnagel CA; Voûte PA; Smets LA
Int J Cancer; 2000 Dec; 90(6):312-25. PubMed ID: 11180134
[TBL] [Abstract][Full Text] [Related]
32. Use of the norepinephrine transporter as a reporter gene for non-invasive imaging of genetically modified cells.
Anton M; Wagner B; Haubner R; Bodenstein C; Essien BE; Bönisch H; Schwaiger M; Gansbacher B; Weber WA
J Gene Med; 2004 Jan; 6(1):119-26. PubMed ID: 14716684
[TBL] [Abstract][Full Text] [Related]
33. Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals.
Du J; Lu WL; Ying X; Liu Y; Du P; Tian W; Men Y; Guo J; Zhang Y; Li RJ; Zhou J; Lou JN; Wang JC; Zhang X; Zhang Q
Mol Pharm; 2009; 6(3):905-17. PubMed ID: 19344115
[TBL] [Abstract][Full Text] [Related]
34. Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides.
Boyd M; Ross SC; Dorrens J; Fullerton NE; Tan KW; Zalutsky MR; Mairs RJ
J Nucl Med; 2006 Jun; 47(6):1007-15. PubMed ID: 16741311
[TBL] [Abstract][Full Text] [Related]
35. Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo.
Ponthan F; Wickström M; Gleissman H; Fuskevåg OM; Segerström L; Sveinbjörnsson B; Redfern CP; Eksborg S; Kogner P; Johnsen JI
Clin Cancer Res; 2007 Feb; 13(3):1036-44. PubMed ID: 17289900
[TBL] [Abstract][Full Text] [Related]
36. Interferon beta-mediated vessel stabilization improves delivery and efficacy of systemically administered topotecan in a murine neuroblastoma model.
Dickson PV; Hagedorn NL; Hamner JB; Fraga CH; Ng CY; Stewart CF; Davidoff AM
J Pediatr Surg; 2007 Jan; 42(1):160-5; discussion 165. PubMed ID: 17208558
[TBL] [Abstract][Full Text] [Related]
37. Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004.
Schmidt M; Simon T; Hero B; Eschner W; Dietlein M; Sudbrock F; Bongartz R; Berthold F; Schicha H
Nuklearmedizin; 2006; 45(4):145-51; quiz N39-40. PubMed ID: 16964339
[TBL] [Abstract][Full Text] [Related]
38. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
Tijink BM; Neri D; Leemans CR; Budde M; Dinkelborg LM; Stigter-van Walsum M; Zardi L; van Dongen GA
J Nucl Med; 2006 Jul; 47(7):1127-35. PubMed ID: 16818947
[TBL] [Abstract][Full Text] [Related]
39. Differential response of tumor cells and normal fibroblasts to fractionated combined treatment with topotecan and ionizing radiation.
Ohneseit PA; Wildemann A; Herskind C; Bamberg M; Rodemann HP
Int J Radiat Biol; 2002 Feb; 78(2):125-32. PubMed ID: 11779362
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and evaluation of 4-[18F]fluoropropoxy-3-iodobenzylguanidine ([18F]FPOIBG): A novel 18F-labeled analogue of MIBG.
Vaidyanathan G; McDougald D; Koumarianou E; Choi J; Hens M; Zalutsky MR
Nucl Med Biol; 2015 Aug; 42(8):673-84. PubMed ID: 25956997
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
